Detection of opioid growth factor in Multiple Sclerosis Patients

Khamael Abdulla Taha; Mayada N. Iqbal; Gheyath Abd Ali Shalal

doi:10.51173/jt.v2i4.258

Authors

Khamael Abdulla Taha College of Health and Medical Technology
Mayada N. Iqbal
Gheyath Abd Ali Shalal

DOI:

https://doi.org/10.51173/jt.v2i4.258

Keywords:

Multiple sclerosis( MS) ; Opioid growth factor(OGF) ; body mass index(BMI)

Abstract

Multiple sclerosis (MS) is a recent prevalent central nervous system disease that affects the brain and spinal cord. It is assumed that it is an intermediate immune disorder in the central nervous system and is complex with incomplete etiology. Some research have confirmed that the Opioid growth factor(OGF), which was called chemically Enkephalin [Met5], is considered as a biomarker for the onset of MS. The purpose of this study was to look into the biomarker level of OGF and its correlation with body mass index(BMI) among patients with MS. A total number of 100 patients were diagnosed in two groups (54 early diagnosis of MS without treatment, 46 early diagnosis with treatment) according to McDonald criteria and 50 healthy control groups were included. All demographic data of the study samples were recorded (age, gender), as well as clinical data such as (BMI),and level OGF(serum and saliva) estimated by ELISA method. The current study revealed that the mean+SD of serum OGF in patients with multiple sclerosis for both groups(947.167 ± 134.262 ng/ml) was less concentrated than the control group (1046.642 ± 63.605 ng/ml) with a very large difference (P <0.01). While the mean concentration of OGF in saliva was (960.158 ± 91.684 ng/ml) for patients with multiple sclerosis (early diagnosis group without treatment and the treatment group), its concentration was higher than the control group (880.059 ± 87.700 ng/ml) with a large statistical significance (P <0.01). The current study showed an important correlation between the body mass index and serum OGF level at (p = 0.022) in the early diagnosis group for multiple sclerosis patients with treatment, , while in the early diagnosis group for multiple sclerosis patients without treatment, a very significant association was found between BMI and serum OGF level at (p = 0.009). Interestingly, the current study showed that saliva biomarker (OGF) would be a good predictor for diagnosing MS.

Downloads

Download data is not yet available.

References

M. AlJumah., R Bunyan., H. Al Otaibi, G. Al Towaijri, A. Karim, Y. Al Malik, H. Algahtani J. B. n.: Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study. 20(1), 49. 2020.

F. Raymond, H.Haraty, Z.Salame ,Y.Fares, D. M. Ojcius ,N.Said Sadier: Salivary biomarkers for the diagnosis and monitoring of neurological diseases. Biomedical Journal 41, pp.63-87. 2018 .

G. Cardamone , E. M. Paraboschi , G. Soldà , S.D.J. Saarela and R.Asselta : Genetic Association and Altered Gene Expression of CYBB in Multiple Sclerosis Patients Biomedicines, 6, 117; doi:10.3390/biomedicines6040117. 2018 .

K. Strimbu and A. Tavel Jorge: What are Biomarkers?. NIH Public Access. ; 5(6): 463–466.2010.

J.N. Snow , K. P. Wadden , A. R. Chaves, and M. Ploughman: Transcranial Magnetic Stimulation as a Potential Biomarker in Multiple Sclerosis: A Systematic Review with Recommendations for Future Research. Hindawi. Neural Plasticity. Volume 2019, Article ID 6430596, 22 pages. 2019.

PJ McLaughlin and IS Zagon : Duration of opioid receptor blockade determines biotherapeutic response. Biochemical Pharmacology .97:236-246.2015.

I. S. Zagon and P. J. McLaughlin : Endogenous Opioids in the Etiology and Treatment of Multiple Sclerosis. Doi:http://dx.doi.org/10.15586/codon.multiplesclerosis .ch8 . 134:1-9. 2017.

I. S. Zagon and P. J. McLaughlin: Endogenous Opioids and the Treatment of Multiple Sclerosis. J Neurol Neurophysiol, S12:S12. 2014.

H.Q. Al-Faradhi X: Study of Some Immunological Parameters in Iraqi Patients with Multiple Sclerosis. A Thesis of Master (Ibn Al-Haitham) University of Baghdad.pp:4-5 . 2015 .

H. A. Mohammed, M. M. kamil, H. N. Aboud and B. Hassan : Multiple Sclerosis Clinic in Iraq, an Endeavourforan Unraveling Database. American Journal of Clinical and Experimental Medicine. Volume 6, Issue 3, pp: 69-82. 2018.

H . S. Ismael : Molecular and immunological study of Multiple Sclerosis patients in Baghdad . A Thesis of Master College of Health and Medical Technology of Baghdad .pp:57 . 2019.

G. Al Gawwam and I. K. Sharquie: Serum Glutamate Is a Predictor for the Diagnosis of Multiple Sclerosis. the Scientific World Journal. Article ID 9320802, p5 .2017.

G.-G. José de Jesús, L. Carrera-Quintanar, R. I. López-Roa, A.L. Márquez-Aguirre, A. E. Rojas-Mayorquín and D. Ortuño-Sahagún: Multiple Sclerosis and Obesity: Possible Roles of Adipokines. Hindawi Publishing Corporation Mediators of Inflammation. Article ID 4036232, p24 . 2016.

S. Wi-Young and K. Alon : The Association between Body Mass Index and Leisure-Time Physical Activity in Adults with Multiple Sclerosis. Int. J. Environ. Res. Public Health, 17, 920.2020.

T. A. Czyzyk, A. Romero-Picó, J. Pintar, J. H. McKinzie, M.H. Tschöp, M. A. Statnick,,and R. Nogueiras: Mice lacking δ-opioid receptors resist the development of diet-induced obesity. FASEB J. 26(8): pp3483–3492. 2012.

Y. Feng, X. He, Y. Yang, D. Chao, L. H. Lazarus, and Y.Xia: Current Research on Opioid Receptor Function. Curr Drug Targets. 13(2): pp230–246. 2012.